27 January 2025
The Russian Ministry of Health has issued a registration certificate to the Russian pharmaceutical company Geropharm for the drug RinLis® (insulin lispro), which is an ultra-fast insulin based on the active substance insulin lispro. This development is a bioanalogue of the drug Lyumjev of Eli Lilly, which never appeared on the Russian market.
According to the press service of Geropharm, large-scale clinical trials conducted in leading Russian scientific centers confirmed the identity of the safety and efficacy profiles of the new and reference drugs. One of the key advantages of the new ultra-fast insulin is the ability to administer it immediately before or within 20 minutes after a meal.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025